The patients were divided into two groups according to Metavir score: F1/F2-group and F3/F4-group. Results: 55/116 (47%) CVH patients were classified in F3/F4-group according to liver stiffness

and 24/61 (39%) according to histology. COMP levels were significantly increased in F3/F4-group either when liver stiffness (p<0.001) or histology (p=0.009) was taken into account. COMP levels correlated with TE measurements (r=0,5, p<0,001) and APRI score (r=0.23, p=0.016). The level of 10 U/L predicted F3/ F4 stage with sensitivity 70% and specificity 82%. Conclusions: COMP serum levels correlated with fibrosis stage assessed by TE, APRI score and liver histology in CVH patients. High COMP levels corresponded to advanced stage, suggesting COMP as a sensitive potential non-invasive biomarker of liver fibrosis. Disclosures: Zakera Shums - Employment: INOVA DIAGNOSTICS Gary selleck chemical L. Norman – Employment: INOVA Diagnostics The following people have nothing to disclose: Stella Gabeta, Kalliopi Zachou, Nikolaos Gatselis, George K. Koukoulis, George N. Dalekos Background/Aims: We developed “Autologous bone marrow cell PD-0332991 cost infusion (ABMi) therapy”. This ABMi therapy is a safe and efficient liver regeneration therapy for liver cirrhotic patients

using non-cultured autologous whole bone marrow (BM) cells, which requires BM aspiration under general anesthesia. We are developing a new liver regeneration therapy using cultured autologous BM-derived mesenchymal stem cells (BMSCs) from small amounts of BM fluid aspirated under local anesthesia. Before human clinical trials, the safety and efficacy of cultured autologous BMSC infusion in medium-to-large animals must be confirmed; thus, we developed a canine liver cirrhotic model. Methods: A small amount of BM fluid was aspirated from canine humerus to assess BMSC characteristics. Repeated oral administration

of carbon tetrachloride (CCl4) ) (0.1 mL/ kg body weight, 5 times/week) was performed over 20 weeks to induce selleck chemicals llc liver cirrhosis. Cultured autologous BMSCs were infused through a peripheral vein. Examination of blood was performed before and at 4 weeks after infusion. We developed another canine liver cirrhotic model using an implanted catheter to shorten the induction time and reduce individual differences compared to oral dosing. CCl4 was repeatedly injected for 10 weeks (high-dose period: 0.75 mL/kg body weight, twice a week for 6 weeks; low-dose period: 0.25 mL/ kg body weight, twice a week for 4 weeks) to induce liver cirrhosis. Cultured autologous BMSCs (4 × 10 5/kg) were infused through a peripheral vein. Low-dose CCl4 was continued after the infusion, and blood examinations, ultrasonography-guided liver biopsies, and indocyanine green (ICG) tests were carried out before and at 4 weeks after infusion. Results: Cultured canine BMSCs adhered to plastic and were CD44+, CD90+, and CD45-.